Phase i trials in melanoma: A framework to translate preclinical findings to the clinic.
One of major issues in clinical trials in oncology is their high failure rate, despite the fact that the trials were designed based on the data from successful equivalent preclinical studies. This is in part due to the intrinsic homogeneity of preclinical model systems and the contrasting heterogeneity of actual patient responses.



We present a mathematical model-driven framework, phase i (virtual/imaginary) trials, that integrates the heterogeneity of actual patient responses and preclinical studies through a cohort of virtual patients. The framework includes an experimentally calibrated mathematical model, a cohort of heterogeneous virtual patients, an assessment of stratification factors, and treatment optimisation. We show the detailed process through the lens of melanoma combination therapy (chemotherapy and an AKT inhibitor), using both preclinical and clinical data.



The mathematical model predicts melanoma treatment response and resistance to mono and combination therapies and was calibrated and then validated with in vitro experimental data. The validated model and a genetic algorithm were used to generate virtual patients whose tumour volume responses to the combination therapy matched statistically the actual heterogeneous patient responses in the clinical trial. Analyses on simulated cohorts revealed key model parameters such as a tumour volume doubling rate and a therapy-induced phenotypic switch rate that may have clinical correlates. Finally, our approach predicts optimal AKT inhibitor scheduling suggesting more effective but less toxic treatment strategies.



Our proposed computational framework to implement phase i trials in cancer can readily capture observed heterogeneous clinical outcomes and predict patient survival. Importantly, phase i trials can be used to optimise future clinical trial design.
Integrated Mathematical Oncology Department, Moffitt Cancer Center and Research Institute, Tampa, FL, USA. Electronic address: Eunjung.Kim@moffitt.org.
Eunjung
E
Kim
The Department of Tumor Biology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Vito W
VW
Rebecca
The Department of Tumor Biology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Keiran S M
KS
Smalley
Integrated Mathematical Oncology Department, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Alexander R A
AR
Anderson
D000465:Algorithms; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003198:Computer Simulation; D004359:Drug Therapy, Combination; D006575:Heterocyclic Compounds, 3-Ring / Q000627:therapeutic use*; D006801:Humans; D066298:In Vitro Techniques; D008545:Melanoma / Q000188:drug therapy*; D008962:Models, Theoretical; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors*; D012878:Skin Neoplasms / Q000188:drug therapy*; D014584:User-Computer Interface
D000970:Antineoplastic Agents; D006575:Heterocyclic Compounds, 3-Ring; C548887:MK 2206; D047428:Protein Kinase Inhibitors; D051057:Proto-Oncogene Proteins c-akt
Clinical trials; Heterogeneity of patient responses; Mathematical model; Stratification; Treatment schedule optimisation
Mol Cancer Ther. 2012 Jan;11(1):154-64
22057914
Br J Cancer. 2012 Sep 25;107(7):1025-30
22910320
Am J Transl Res. 2014 Jan 15;6(2):114-8
24489990
Nature. 2004 Nov 18;432(7015):294-7
15549090
J Clin Oncol. 2009 Sep 1;27(25):4103-8
19636014
Pigment Cell Melanoma Res. 2014 May;27(3):465-78
24490764
Nat Rev Drug Discov. 2011 Feb;10(2):87
21283095
Clin Cancer Res. 1995 Jun;1(6):599-606
9816021
J Clin Invest. 2014 Mar;124(3):1406-17
24569374
J Hematol Oncol. 2014 Jan 03;7:1
24387695
J Natl Cancer Inst. 2012 Apr 18;104(8):590-8
22491345
Nature. 2013 Feb 14;494(7436):251-5
23302800
Cancer Res. 2014 Feb 1;74(3):647-51
24459182
Cell. 2005 Sep 23;122(6):927-39
16179260
Cell Death Differ. 2015 Mar;22(3):367-76
25257169
Eur J Cancer. 2009 Jan;45(2):228-47
19097774
Nat Rev Cancer. 2005 Sep;5(9):726-34
16148885
N Engl J Med. 2011 Jun 30;364(26):2507-16
21639808
Clin Pharmacol Ther. 2010 Aug;88(2):166-82
20613720
Nat Rev Cancer. 2012 Apr 26;12(6):401-10
22534666
Cancer Cell. 2009 Aug 4;16(2):103-14
19647221
Nature. 2011 Sep 28;477(7366):526-8
21956311
Curr Gene Ther. 2009 Oct;9(5):368-74
19860651
Cell. 2014 Jan 30;156(3):603-616
24485463
Lancet Oncol. 2012 Mar;13(3):236
22489289
J Clin Oncol. 2011 Dec 10;29(35):4688-95
22025163
Crit Care Med. 2004 Oct;32(10):2061-70
15483415
Autophagy. 2012 May 1;8(5):739-53
22498493
Br J Cancer. 1997;75(2):287-94
9010040